CSBio CSBio

X
[{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ORYZON to Present New Clinical Data and Corporate Updates at International Conferences in May and June","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SPAIN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Oryzon Genomics"},{"orgOrder":0,"company":"Peptomyc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Peptomyc\u2019s OMO-103, Has Obtained Approval for First-in-Human Phase I","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SPAIN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Peptomyc"},{"orgOrder":0,"company":"IDP Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IDP Pharma Announces First Patient Dosed in a Phase 1\/2 Clinical Trial of IDP-121, a Direct cMyc Protein Inhibitor and Degrader","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SPAIN","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Peptide","graph2":"IDP Pharma"},{"orgOrder":0,"company":"3P Biopharmaceuticals","sponsor":"Buzzard Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"3P Biopharmaceuticals and Buzzard Pharmaceuticals Start a Collaboration to Develop a New Treatment to Combat Solid Tumours","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SPAIN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"3P Biopharmaceuticals"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            IDP-121 is a potent, selective peptidomimetic that acts by simultaneously obstructing the formation of the cMyc/Max complex while also augmenting cMyc degradation through the intrinsic cellular machinery.

            Lead Product(s): IDP-121

            Therapeutic Area: Oncology Product Name: IDP-121

            Highest Development Status: Phase I/ Phase II Product Type: Peptide

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 26, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            A first in man Phase I/IIa clinical trial with iadademstat in refractory and relapsed acute leukemia patients demonstrated safety and good tolerability of the drug.

            Lead Product(s): Iadademstat

            Therapeutic Area: Oncology Product Name: ORY-1001

            Highest Development Status: Phase I/ Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 13, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            3P Biopharmaceuticals and Buzzard Pharmaceuticals have entered into a partnership agreement for manufacturing of the potent IL-1 inhibitor Isunakinra, a recombinant protein for cancer indications.

            Lead Product(s): Isunakinra

            Therapeutic Area: Oncology Product Name: EBI-005

            Highest Development Status: Phase I/ Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Buzzard Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration May 07, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Peptomyc has received approval from the Spanish Agency of Medicines and Medical Devices for conducting clinical trials in Spain (AEMPS), to initiate the first-in-human Phase I/II clinical trial with its first compound - a disruptive Myc inhibitor, Omomyc (OMO-103).

            Lead Product(s): Omomyc

            Therapeutic Area: Oncology Product Name: OMO-103

            Highest Development Status: Phase I/ Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 18, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY